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Abstract: The serine protease Caseinolytic protease subunit P (ClpP) plays an important role for protein
homeostasis in bacteria and contributes to various developmental processes, as well as virulence.
Therefore, ClpP is considered as a potential drug target in Gram-positive and Gram-negative bacteria.
In this study, we utilized a biochemical assay to screen several small molecule libraries of approved and
investigational drugs for Escherichia coli ClpP inhibitors. The approved drugs bortezomib, cefmetazole,
cisplatin, as well as the investigational drug cDPCP, and the protease inhibitor 3,4-dichloroisocoumarin
(3,4-DIC) emerged as ClpP inhibitors with IC50 values ranging between 0.04 and 31 µM. Compound
profiling of the inhibitors revealed cefmetazole and cisplatin not to inhibit the serine protease bovine
α-chymotrypsin, and for cefmetazole no cytotoxicity against three human cell lines was detected.
Surface plasmon resonance studies demonstrated all novel ClpP inhibitors to bind covalently to ClpP.
Investigation of the potential binding mode for cefmetazole using molecular docking suggested a
dual covalent binding to Ser97 and Thr168. While only the antibiotic cefmetazole demonstrated
an intrinsic antibacterial effect, cDPCP clearly delayed the bacterial growth recovery time upon
chemically induced nitric oxide stress in a ClpP-dependent manner.
Keywords: Escherichia coli; ClpP; high-throughput screening; inhibitor; surface plasmon resonance;
covalent binding; nitric oxide stress
1. Introduction
Antimicrobial resistance of Gram-negative bacteria has increased significantly over the last
decades [1,2]. Therefore, novel approaches for antimicrobial therapies are urgently needed. Classical
antibiotics inhibit protein synthesis, cell wall synthesis, depolarization of the membrane potential, folate
synthesis, and DNA or RNA synthesis [3]. Caseinolytic protease subunit P (ClpP) is a well-conserved
serine protease in bacteria and many eukaryotes, and absent in archaea and mollicutes [4,5]. Several
studies have shown that 80% of cellular proteolysis in bacteria is dependent on the proteases ClpP and
La (Lon) [6], thus suggesting a major role of ClpP in bacterial homeostasis and pathogenesis [6,7].
ClpP is a tetradecameric protein composed of two heptameric rings, which are assembled
back-to-back, resulting in the formation of a proteolytic chamber which is connected to the cytoplasm
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via two axial channels [8]. The peptidase activity of ClpP results in peptides of seven to eight residues
in length [9]. Members of the AAA+ superfamily (ATPases associated with diverse cellular activities),
such as ClpX and ClpA in E. coli, bind to the two axial channels of tetradecameric ClpP and initiate
substrate recognition, unfolding, and threading of the unfolded protein chain into the proteolytic
chamber of ClpP [10–12].
To date, about 70 proteins have been identified as substrates for E. coli ClpP-mediated proteolytic
cleavage [13]. In E. coli, ClpP is involved in metabolism, damage repair, cell division, transcriptional
regulation, and stress response [14]. In other bacteria, ClpP contributes to oxidative stress response
(Streptococcus pneumoniae) [15], virulence (Staphylococcus aureus) [16,17], biofilm formation and motility
(Pseudomonas aeruginosa) [18]. It has also been shown that ClpP is essential for macrophage infection
(Listeria monocytogenes) [19]. Impaired virulence and reduced translocation of effector proteins have
been observed for clpP-deficient Legionella pneumophila [20]. Due to its wide range of relevant functions,
ClpP is considered as a highly promising target for antibiotics [7]. Recently, differences in growth
curves between wild-type (WT) and clpP-deficient E. coli strains under nitric oxide stress conditions
suggested that targeting ClpP also in Gram-negative bacteria might represent a promising therapeutic
approach [14].
Several small molecules have been described to inhibit ClpP activity, including phenyl esters,
boronates, AV145 and the covalently binding benzyloxycarbonyl-leucyl-tyrosine chloromethyl ketone
(Z-LY-CMK) [21–23]. Additionally, several β-lactones have been shown as active against various ClpPs
of pathogenic and nonpathogenic bacterial strains [7]. Recently, we have reported α-amino diphenyl
phosphonates as potent inhibitors of ClpP in E. coli [24]. Besides inhibitors, enzyme activators have
also been described that activate ClpPs by preventing ClpA or ClpX binding to ClpP, thereby resulting
in uncontrolled proteolysis by the enzyme [8].
In this study, we aimed to identify novel small molecules inhibiting E. coli ClpP. For this purpose,
we screened three small molecule libraries containing approved and investigational drugs using a
high-throughput biochemical assay. Validated ClpP inhibitors were further characterized for enzyme
selectivity, cell toxicity, protein binding, and antimicrobial properties.
2. Results
The small molecule libraries SCREEN-WELL® FDA approved drug library version 2
(774 compounds), LOPAC®1280 (1280 compounds) and a set of matrix metalloproteinase (MMP)
inhibitors (329 compounds) were screened for E. coli ClpP inhibition. DMSO and the already known
ClpP inhibitor Z-LY-CMK were used as negative or positive control, respectively. In order to assess the
validity of the screening campaign, the Z’ value was calculated for each microtiter plate [25]. For all
screened plates, Z’ was at least 0.6 (Figure S1), thus indicating an acceptable assay performance [26].
The primary screen resulted in 24 compounds inhibiting ClpP by >70% of which six compounds
showed >90% enzyme inhibition: cisplatin, cDPCP, bortezomib, 3,4-dichloroisocoumarin (3,4-DIC),
cefmetazole, and guanabenz (Table S1).
Hit validation was carried out by testing the six most potent compounds in dose-response.
This confirmed five primary hits (Figure 1) as ClpP inhibitors with IC50 values ranging from 0.04 to
31.0 µM (Figure S2, Table 1). The confidence interval varied between 0.02 and 44.8. Only guanabenz
did not confirm as ClpP inhibitor. With an IC50 of 0.04 µM, bortezomib emerged as the most potent
compound in this study. For comparison, cefmetazole and 3,4-DIC exhibited a more than 100-fold
lower potency. Cisplatin and cDPCP proved to be the least potent ClpP inhibitors. None of the other
cephems and penems included in the screened compound libraries showed a ClpP inhibition exceeding
70% (Table S2). The positive control Z-LY-CMK revealed an IC50 value above 10 µM.
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Table 1. Overview of IC50 values of identified ClpP inhibitors and the positive control (Z-LY-CMK),
confidence interval (CI) as well as inhibition of E. coli ClpP and bovine α-chymotrypsin at 200 µM
compound concentration.
Compound E. coli ClpP Inhibition (%) at 200 µM
IC50 (µM) CI E. coli ClpP α-Chymotrypsin
Bortezomib 0.04 0.02–0 05 100.1 97.8
Cefmetazole 3.4 1.5–7.6 94.5 0
cDPCP 24.6 17–36 91.2 84.7
Cisplatin 31 21.4–44.8 96.5/98.7 1 0
3,4-DIC 4.9 3.3–7.2 98.9 101.4
Z-LY-C 14 11.0–16.6 98.6 99.8
1 Cisplatin emerged as hit in both screened libraries of approved and investigational drugs.
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Table 2. Cytotoxicity potential of ClpP inhibitors against the human cell lines HTC-116, MCF-7, and
A549 as quantified by a luminescent cell viability assay (IC50). The ratio compares the results with
ClpP inhibition as shown in Table 1 (IC50 cytotoxicity/IC50 ClpP).
Compound Cytotoxicity
HTC-116 MCF-7 A549
IC50 (µM) Ratio IC50 (µM) Ratio IC50 (µM) Ratio
Bortezomib 0.0002 0.005 0.04 1 0.0002 0.005
Cefmetazole 5430 1597.06 74.12 21.8 250 73.53
cDPCP 283 11.5 3.27 0.13 131 5.33
Cisplatin 913 29.45 4.52 0.15 86.7 2.8
3,4-DIC 45.1 9.2 9.06 1.85 44.7 9.12
Z-LY-CMK 3.54 0.25 0.05 0 7.15 0.51
In a next step, we assessed whether the identified inhibitors bind covalently or non-covalently to
ClpP using surface plasmon resonance (SPR) spectroscopy. Test compounds were injected into the flow
cell at 80 µM concentration. As the SPR signal did not return to baseline after 30 min, all novel ClpP
inhibitors were expected to irreversibly bind to the enzyme (Figure 2A–E). While the already known
covalent inhibitor Z-LY-CMK confirmed as an irreversibly binding compound (Figure 2F), caffeine,
used as a non-binding control, did not show any interaction with ClpP (Figure S3). Measurements
with bortezomib revealed a low change of absolute resonance unit (RU) (Figure 2A), even though this
compound exhibits a nanomolar IC50 value in the enzymatic assay. This effect could be due to partial
dissociation effects or induction of intramolecular conformational changes upon binding. For cisplatin
and cDPCP we obtained high RU values, indicating unspecific binding of both compounds to the
protein (Figure 2C,D).
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Figure 2. SPR sensorgrams t ClpP inhibitors at 80 µM con entration. Each compound was injected
ov r 7 min, followed by 30 min of dissociation time. (A) Bortezomib, (B) Cefmetazole, (C) cDPCP,
(D) Cisplatin, (E) 3,4-DIC, and (F) Z-LY-CMK (covalent binder, cont ol). The fitting curves of the SPR
sensorgrams (black lines) were obtained using a 1:1 L ngmuir interaction model.
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In order to evaluate the potential binding mode of cefmetazole in the active site of ClpP, the
compound was docked into the X-ray crystal structure of the enzyme (Protein Data Bank ID 2FZS).
Due to the experimentally-confirmed irreversible binding to ClpP, cefmetazole was docked with the
β-lactam ring in the open conformation and covalently bound to Ser97 of the catalytic triad, which is
the most frequent covalent interaction point for penem-class antibiotics [27]. The binding mode of the
top-ranked docking pose within the active site showed several hydrogen bonds shared with the protein
(Figure 3). Notably, the potentially reactive nitrile moiety is placed in close proximity to Thr168.
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Figure 3. Binding mode of cefmetazole (carbon atoms in cyan) in ClpP obtained by molecular docking
into Protein Data Bank (PDB) ID 2FZS using GOLD with the compound covalently attached to the
hydroxyl oxygen of Ser97. Hydrogen bonds and C–H–pi interactions are indicated as green and cyan
dashed lines, respectively.
In a next step, the compounds were tested for any intrinsic antimicrobial activity against wild-type
E. coli BW25-113 and the isogenic ClpP-deficient strain E. coli JW0427 (∆clpP) at a concentration of
100 µM in rich Mueller Hinton broth medium (MHB). Only the antibiotic cefmetazole inhibited growth
of both strains at 100 µM concentration (Table 3), while all other compounds did not affect bacterial
growth. In addition, the compounds were tested in E. coli JW5503 (∆tolC), an efflux pump-defective
strain. Except cefmetazole, none of the compounds showed improved antibacterial activity. The fact
that cefmetazole completely inhibited bacterial growth of the tested strains is consistent with its role as
an antibiotic; therefore, we excluded the compound from further antimicrobial investigations in this
study. Next, bortezomib, cisplatin, cDPCP, and 3,4-DIC were evaluated for growth inhibition of E. coli
BW25-113 and E. coli JW0427 in presence of the known efflux pump inhibitor Phe-Arg β-naphthylamide
(PAβN, 25 µM). Of the tested compounds, bortezomib resulted in 55% growth inhibition in the WT
strain and, interestingly, 100% in the clpP-deficient mutant (Table 3).
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Table 3. Antibacterial evaluation of the ClpP inhibitors. All compounds were tested at 100 µM
concentration and growth inhibition was measured after 24 h of incubation at 37 ◦C.
Strain PAβN Compound Growth Inhibition (%)
E. coli WT - Cefmetazole 100
+ Cefmetazole 100
E. coli ∆clpP - Cefmetazole 100
+ Cefmetazole 100
E. coli ∆tolC - Cefmetazole 100
E. coli WT + Bortezomib 55
E. coli ∆clpP + Bortezomib 100
Recently, it has been shown that clpP-deficient E. coli shows an impaired nitric oxide (NO•)
detoxification capacity compared to WT E. coli after nitric oxide stress induction using DPTA NONOate,
which spontaneously dissociates and thereby releases two NO•molecules per parent compound [14].
In order to investigate the effect of the novel ClpP inhibitors on the capability of bacteria to recover
from nitric oxide stress, compounds were tested at 50 and 100 µM against wild-type E. coli BW25-113
in minimal medium M9, in the presence or absence of DPTA NONOate, respectively. The isogenic
mutant E. coli JW0427 (∆clpP) was used as positive control.
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Figure 4. Bacterial growth curves of WT and ∆clpP E. coli strains in minimal media and in presence
(solid lines) and absence (dotted lines) of DTPA NONOate (NO•). OD600 was measured in absence (A)
and presence of 50 µM (B) cisplatin (C) cDPCP and (D) 3,4-DIC. Each value represents the mean of
three independent experiment ± standard deviation.
Untreated WT and ∆clpP E. coli strain revealed similar growth within the first three hours, while
the mutant E. coli str in continued with slowe growth afterwards and did not reach the sam optical
density (OD600) level as the WT strain within 24 h (Figure 4A). Using a rich medium (Mueller Hinton
broth), the clpP-deficient str in also grew slo er; however, both strains reached an almost identical
optical density after 24 h (Figure S4). Treatment ith the NO• donor DPTA NONOate resulted in a
~3 h growth arrest for the wild-type strain and ~4 h for ∆clpP E. coli. In presence of 50 µM cisplatin, th
bacterial growth was comparable to the untreat d b cteria (Figure 4B). Administration of cisplatin
in presence of DPTA NONOate resulted in a signific ntly l nger growth arrest (~10 h) compared to
untreated WT and mutant E. coli in presence of • stress. At a higher compound concent ation
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(100 µM), cisplatin affected bacterial growth in the absence of NO• stress, probably due to toxicity
(Figure S5A). cDPCP alone did not influence bacterial growth at both tested concentrations (Figure 4C
and Figure S5B). When exposed to nitric oxide stress, cDPCP-treated WT bacteria recovered later than
the stressed WT strain without compound addition. The bacterial growth in the first 11 h was identical
to the growth of nitric oxide stress-exposed E. coli lacking ClpP (Figure 4C). At 100 µM concentration
(Figure S5B), WT cell growth was clearly influenced by the compound itself. Experiments using
3,4-DIC resulted in very similar growth curves at both tested concentrations (Figure 4D and Figure
S5C). We observed a small growth delay of non-stressed WT E. coli in the presence of the compound
compared to untreated bacteria. A similar effect occurred in bacteria co-treated with DPTA NONOate.
Bortezomib did not show any effect on growth curves, both in the absence and presence of nitric oxide
stress (data not shown).
After 24 h, all bacteria exposed to test compounds (except cisplatin and cDPCP at 100 µM) and
nitric oxide stress conditions reached an OD600 level comparable to WT E. coli, exceeding the growth
levels of the mutant (Figure 4).
In order to evaluate whether the observed compound effects on growth delay are ∆clpP-mediated,
the compounds were tested at the same conditions in clpP-deficient E. coli. The absence of nitric oxide
stress did not result in any significant growth curve differences compared to untreated cells (Figure S6).
In presence of nitric oxide stress, cisplatin showed a significantly longer growth delay compared to
DPTA NONOate-exposed cells in the absence of any compound. In contrast, cDPCP and 3,4-DIC did
not show any significant effect in clpP-deficient E. coli, and upon induction of nitric oxide stress the
growth delay was virtually identical to the bacteria without compound treatment (Figure S6).
3. Discussion
Based on a biochemical high-throughput screen, we identified five novel and structurally distinct
inhibitors of E. coli ClpP. These comprise two approved drugs and one investigational drug used as
cancer therapeutics, an antibiotic, which is known to be active against Gram-positive and -negative
bacteria, as well as a serine protease inhibitor. All ClpP inhibitors were profiled with respect to serine
protease selectivity, the binding mode, the cytotoxic potential, as well as the intrinsic antimicrobial
activity. In addition, we also investigated the nitric oxide (NO•) detoxification capacity of wild-type
E. coli and a ClpP-deficient strain in the presence and absence of compounds. We confirmed the
reported growth delay of the ∆clpP mutant as described by Robinson and Brynildsen [14], although in
this study the differences between both strains were less pronounced. Moreover, our data did not show
the mutant E. coli strain to reach the same optical density (OD600) level as the WT strain within 24 h, as
described in the initial study [14], neither in the presence nor absence of NO• stress. Possibly, this is
due to different strains used in the previous study as well as the assay setup, as shown by the growth
curves in MHB medium. Alternatively, it may indicate another effect that relates to the importance
of ClpP in mediating bacterial growth in conditions associated with resource shortage, (i.e., minimal
medium conditions). Moreover, a strain-dependent effect cannot be excluded.
The anticancer compounds cisplatin and cDPCP revealed the highest IC50 values of the five novel
ClpP inhibitors. Cisplatin did not show any inhibition of bovine α-chymotrypsin in this study, even at a
high concentration of 200 µM. In contrast, cDPCP potently inhibited the enzyme. Cisplatin and cDPCP
are metal-containing compounds used in chemotherapy. While cisplatin acts by DNA cross-linking,
cDPCP makes a single mono-functional adduct with DNA due to a single chlorine atom that acts as a
leaving group [28]. Due to the known mechanism of action of both compounds, the covalent interaction
with ClpP is not unexpected. Considering the therapeutic area of these substances, the pronounced
cytotoxicity of cDPCP and cisplatin is not surprising. Notably, both compounds showed antibacterial
activity when applied in the presence of nitric oxide stress. While the effect of cisplatin on bacterial
growth seems to be ClpP-independent, cDPCP appears to affect E. coli growth in a ClpP-mediated
manner. Besides cisplatin and cDPCP, another platinum-containing compound was included in the
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screened compound libraries (carboplatin). However, the substance did not show any significant
enzyme inhibition (5.4%).
The third anticancer drug identified as ClpP inhibitor in this study, bortezomib, inhibited the
enzyme with an IC50 value in the nanomolar range and potently antagonized bovine α-chymotrypsin.
No other compound structurally similar to bortezomib was included in the screened small molecule
libraries. In mammalian cells, bortezomib acts as covalent and reversible inhibitor of the proteolytic
activity of the 26S proteasome complex with high affinity and specificity [29]. Recently, it has been
described as ClpP inhibitor in Mycobacterium tuberculosis [23]. Bortezomib is a dipeptidyl boronic acid
and is chemically similar to the already known E. coli ClpP inhibitor Z-LY-CMK [21]. In agreement
with literature data, bortezomib was confirmed as highly cytotoxic. As for the other two anticancer
compounds, cisplatin and cDPCP, surface plasmon resonance studies revealed covalent binding of
bortezomib to ClpP. Interestingly, in E. coli treated with the efflux pump substrate PaβN, bortezomib
showed complete growth inhibition of the ∆clpP mutant, while the WT cell line growth was reduced
to only 55%. This is possibly due to a combination of an off-target effect, which is unrelated to the
inhibition of ClpP, and the clpP deletion.
3,4-DIC, is a general serine protease inhibitor targeting elastase-like, chymotrypsin-like, and
trypsin-like proteases by acylation of the catalytic serine residue [30]. This explains the potent inhibition
of both tested proteases in this study. As for bortezomib, no compounds structurally similar to 3,4-DIC
were included in the screened small molecule libraries. 3,4-DIC revealed covalent binding to ClpP
and did not show any intrinsic antimicrobial activities. In addition, the compound exhibited a limited
effect on bacterial growth in the presence of nitric oxide stress.
Finally, we identified ClpP as a new intracellular target for cefmetazole, a second-generation
cephalosporin. The enzyme inhibition assays revealed a low IC50 for E. coli ClpP and no inhibition
of α-chymotrypsin. Moreover, the compound did not show cytotoxicity against human cell lines at
therapeutically relevant concentrations. Cefmetazole interferes with transpeptidation and cross-linking
during cell wall synthesis [27,31]. Covalent compound binding to penicillin-binding proteins involves
a nucleophilic serine to attack the C–N bond of the β-lactam ring [27]. Therefore, a similar interaction
with Ser97 of the active site appears to be the mechanism of action of cefmetazole in ClpP. Notably, the
screened small molecule libraries in this study contained 43 additional cephems and penems and none
of these compounds showed ClpP inhibition in the primary screen above >70%. Within the screened
compound libraries, cefazolin, ceftriaxone, and cefotetan are structurally most similar to cefmetazole,
as determined using a similarity search. However, none of these compounds revealed a significant
ClpP inhibition in the primary screen (between −4.6% and 19.3%).
An explanation for the differences in enzyme inhibition might be the nitrile moiety in cefmetazole,
which is not present in any other cephem or penem tested in this study. As nitrile groups may
covalently react with amino acid side chains [32], cefmetazole may bind via two covalent bonds to
ClpP. Molecular docking confirmed the possibility of two covalent bonds between the open β-lactam
ring form of cefmetazole and Ser97, as well as Thr168 (via the nitrile moiety). In order to investigate
this hypothesis, further experimental studies are required. In fact, the existence of two covalent bonds
between a ClpP inhibitor and the enzyme has been shown in the X-ray crystal structure of ClpP in
complex with Z-LY-CMK, involving Ser97 and His122 of the catalytic triad. A dual covalent binding
mechanism of action might be exploited for the development of ClpP-specific inhibitors that may serve
as adjuvants in antimicrobial therapies.
4. Materials and Methods
4.1. Protein Production
Plasmid pETDclpPec (ORF ECK0431) [33] was inserted into E. coli SG1146a. After overnight
incubation, bacteria were diluted in fresh LB medium containing 100 µg/mL ampicillin, and were
grown until an OD600 of 0.6 was reached. Isopropylβ-D-1-thiogalactopyranoside (1 mM) was added for
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induction and flasks were placed in an orbital shaker for 5 h at 30 ◦C and 180 rpm. Cells were lysed on
ice with a homogenizator (Precellys Evolution, Bertin Technologies, Montigny-le-Bretonneux, France).
Protein was purified by immobilized metal affinity chromatography (IMAC) with a Ni-NTA His-tag
resin column (Sigma Aldrich, Taufkirchen, Germany) using buffers with increasing concentration of
imidazole (Buffer A: pH 7.6, 50 mM Tris-HCl buffer, 150 mM NaCl, 10 mM imidazole. Buffer B: pH 7.6,
50 mM Tris-HCl buffer, 150 mM NaCl, 20 mM imidazole. Buffer C: pH 7.6, 50 mM Tris-HCl buffer,
150 mM NaCl, 500 mM imidazole). Buffer exchange was carried out using PD 10 desalting columns
(GE Healthcare, Little Chalfont, UK) with buffer D (pH 7.6, 20 mM Tris-HCl buffer, 100 mM NaCl,
5 mM MgCl, 10% (v/v) glycerol).
4.2. Primary Screening and Hit Confirmation
The SCREEN-WELL® FDA-approved drug library V2 was purchased from Enzo Life Sciences,
and the LOPAC®1280 library was obtained from Sigma-Aldrich (Taufkirchen, Germany). Moreover,
a set of 329 MMP inhibitors was obtained from Specs (Zoetermeer, Netherlands). MMP inhibitors
were dissolved at 10 mM concentration in 99.8% DMSO (ROTIPURAN®, Carl Roth GmbH, Karlsruhe,
Germany) and stored at −20 ◦C until usage. Z-LY-CMK (Bachem, Bubendorf, Switzerland) was used as
positive inhibition control.
The primary screen was carried out using a compound concentration of 200 µM. The proteolytic
activity of ClpP in the presence of test compounds was assessed using a fluorescence-based
assay in 384-well plate format (black, flat-bottom microtiter plates, #3820, Corning Inc., Corning,
NY, USA), carried out on a FluentTM 780 laboratory automation system (Tecan, Männedorf,
Switzerland). Briefly, 25 ng/µL of E. coli ClpP dissolved in a buffer containing 100 mM NaCl,
100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, and 0.05% Brij® 35 were
transferred into each well. Test compound addition (final concentration 200 µM) was carried out using
an Echo® 550 liquid handling system (Labcyte, Sunnyvale, CA, USA). Protein and test compounds
were incubated for 10 min at 30 ◦C, followed by addition of the fluorogenic substrate Suc-LY-AMC
(75 µM, Enzo Life Sciences, Lörrach, Germany). Changes in fluorescence (excitation 350 nm, emission
435 nm) were monitored at 1 min intervals at 30 ◦C over 1 h using an Infinite M1000 microplate reader
(Tecan).
For hit confirmation, 3,4-DIC (#D7910), cDPCP (#C0996) and cisplatin (#P4394) were obtained
from Sigma-Aldrich (St. Louis, MO, USA), cefmetazole sodium (#KS-1415) and guanabenz acetate
(#KS-1362) from Key Organics (UK), and bortezomib (#T2399) from TargetMol (Boston, MA, USA).
All compounds were dissolved in DMSO (99.9%), resulting in 10 mM stock solutions. The assay was
carried out as described above with increasing concentrations of test compounds. Dose-response
experiments were done at least 3 times independently, each in technical triplicates.
Compound selectivity was assessed using bovine α-chymotrypsin (#C4129, Sigma-Aldrich,
St. Louis, MO, USA) at 200 µM. The assay was carried out as described above, except that 1 ng/µL of
α-chymotrypsin and 100 µM of Suc-LY-AMC substrate were dissolved in a buffer containing 150 mM
NaCl, 10 mM CaCl2, 50 mM Tris-HCl, and 0.05% Brij® 35.
4.3. Surface Plasmon Resonance Spectroscopy
E. coli ClpP (80 µg/mL) protein was immobilized, using amine coupling (SPR-AS-HCA-03,
Bruker Daltonics Inc., Billerica, MA, USA), onto the surface of the sensor chip of a SIERRA SPR-16
instrument (Bruker Daltonics GmbH, Bremen, Germany). ClpP protein was dissolved in acetate at
pH 4. The running buffer contained 150 mM NaCl, 10 mM Hepes, 3 mM EDTA, and 0.05% (v/v)
Tween-20. The flow rate for protein immobilization was 10 µL/min. Binding experiments were carried
out using running buffer with the addition of 0.8% (v/v) of DMSO and 80 µM test substance (flow rate
of 20 µL/min for 7 min and up to 30 min of dissociation time). The positive control for covalent binding
was Z-LY-CMK, while caffeine was used as non-binding control. SPR data were analyzed using the
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Analyzer 3 software (Bruker Daltonics GmbH), which includes algorithms for subtracting reference
signals and accounting for non-specific interactions between the solvent and the sensor chip surface.
4.4. Cell Viability Assays
Potential cell toxicity of the tested compounds was evaluated by ATP quantification using the
CellTiter-Glo® luminescent cell viability assay (Promega, Madison, WI, USA). A549, HTC-116 and
MCF-7 cells were seeded at 2000 cells/well (20 µL) in white, flat-bottom, sterile 384-well plates (#781073,
Greiner Bio-One GmbH, Frickenhausen, Germany) and incubated for 24 h. A total of 200 nL ClpP
inhibitors plus positive (valinomycin, 10 µM) and negative (DMSO, 1%) controls were transferred in
the plate, using an Echo® 550 liquid handler (Labcyte) at 1:3 dilutions, starting from 200 µM, and
incubated for an additional 48 h (95% air, 5% CO2 at 37 ◦C). After incubation, 20 µL of CellTiter-Glo®
reagent were added per well and incubated at room temperature in the dark for another 30 min.
Luminescence was quantified by an EnVision multi-plate reader (PerkinElmer, Rodgau, Germany).
4.5. Antibacterial Assays
The potential of hit compounds to interfere with bacterial growth was evaluated in E. coli BW25-113
(wild type) and tolC-deficient strain E. coli JW5503 [34] (obtained from the NBRP-E. coli collection at the
National Institute of Genetics, Mishima, Japan). The effect of the compounds on wild-type strain E. coli
BW25-113 and the isogenic clpP-deficient E. coli JW0427-1 [34] (coli genetic stock center, New Haven,
CT, USA) were measured in the presence of the efflux pump inhibitor Phe-Arg β-naphthylamide
dihydrochloride (#P4157, Sigma-Aldrich, USA) at 25 µM. Single colonies of the bacterial strains from
Mueller Hinton Agar culture were used to inoculate 5 mL of saline solution. The suspension was
transferred into fresh, sterile Mueller Hinton broth (MHB) medium, resulting in a final concentration of
106 CFU/mL. Growth assays were carried out in 96-well, flat-bottom, sterile clear plates (#167008, Nunc,
VWR, Radnor, PA, USA) and compounds were tested at 50 and 100 µM concentration (2% DMSO).
Absorbance at 600 nm was measured using the Multiskan GO or Varioskan LUX plate reader (Thermo
Fisher Scientific, Vantaa, Finland) for 24 h at hourly intervals. Between measurements, plates were
incubated in a shaking incubator (500 rpm) at 37 ◦C.
Assessment of E. coli growth delay in presence of nitric oxide stress was carried out following
our recently published protocol [24], which is an adaptation of the method reported by Robinson
and Brynildsen [14] to a 96-well plate format. Fresh MHB medium was inoculated with isolated
colonies of E. coli BW25-113 or E. coli JW0427-1, grown on Luria Agar, and left overnight in a
shaking incubator (250 rpm) at 37 ◦C. On the following day, the overnight culture was used
to inoculate fresh M9 medium (supplemented with 10 mM glucose) 1:100, and was grown until
OD600 ~0.3. Afterwards, the culture was transferred into 96-well, flat-bottom, sterile clear plates
(#167008, Nunc, VWR). Bacterial OD600 was adjusted to 0.1 with M9 medium (supplemented with
10 mM glucose). Test compounds were transferred into the 96-well plates, followed by addition
of the bacterial culture. Nitric oxide stress was induced by addition of 2 mM DPTA NONOate
((Z)-1-[N-(3-aminopropyl)-N-(3-ammoniopropyl)amino]diazen-1-ium-1,2-diolate, Cayman Chemical,
Ann Arbor, MI, USA), dissolved in NaOH (final concentration 0.14 mM). Absorbance measurements
(600 nm) were done with a Multiskan GO or Varioskan LUX plate reader (Thermo Fisher Scientific,
Finland) at hourly intervals for 24 h. Between measurements, plates were incubated in a shaking
incubator (500 rpm) at 37 ◦C.
4.6. Data Analysis
Calculation of Z prime (Z’) for HTS assay performance was done according to Zhang et al. [25].
Plates were considered for further analyses if Z’ > 0.6 [26]. IC50 values were determined by a
non-linear fit using the equation for sigmoidal dose-response with variable slope in GraphPad Prism
7.03 (GraphPad software, La Jolla, CA, USA).
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4.7. Molecular Docking and Similarity Search
The ClpP X-ray crystal structure was obtained from the Protein Data Bank (PDB ID 2ZFS). Of the 14
chains, chain B was selected based on structural quality analysis of all chains using PROCHECK [35] and
ProSa [36]. The protein structure was prepared using the software Molecular Operating Environment
(MOE, Chemical Computing Group Inc., Montreal, QC, Canada) version 2016.0802. Three-dimensional
coordinates of cefmetazole were generated within MOE. Molecular docking was carried out using
GOLD version 5.6.1 (Cambridge Crystallographic Data Centre, Cambridge, UK) and the GoldScore
scoring function. GoldScore revealed the best redocking performance of all four implemented scoring
functions when redocking the co-crystallized ligand Z-LY-CMK in terms of root-mean-square deviation
between ligand crystal coordinates and the top-ranked docking pose. The search space was defined as
a sphere of radius 15 Å centered on atom OG of Ser97. Altogether, 50 docking runs were conducted.
The early termination option was disabled and the side chain of Asn150 was defined as flexible.
The similarity search was carried out using MOE. For all compounds in the screened compound
libraries, molecular fingerprints (Bit-Packed MACCS structural keys) were calculated. A similarity
threshold of 70% was applied for searching compounds structurally similar to the confirmed
primary hits.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/11/
2686/s1.
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Abbreviations
CI Confidence interval
ClpP Caseinolytic protease subunit P
HTS High-throughput screening
MMP Matrix metalloproteinase
Z-LY-CMK benzyloxycarbonyl-leucyl-tyrosine chloromethyl ketone
3,4-DIC 3,4-dichloroisocoumarin
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